Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 11, 2013 - Issue 1
Submit an article Journal homepage
75
Views
10
CrossRef citations to date
0
Altmetric
Special Report

Microbicides for the prevention of sexually transmitted HIV infection

Quarraisha Abdool Karim CAPRISA – Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa; Department of Epidemiology, Columbia University, NY, USA. [email protected]; Department of Epidemiology, Columbia University, NY, USA. [email protected]
&
Cheryl Baxter CAPRISA – Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa; CAPRISA – Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa
Pages 12-23 | Published online: 10 Jan 2014

References

  • Pettifor AE, Rees HV, Kleinschmidt I et al. Young people’s sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 19(14), 1525–1534 (2005).
  • Shisana O, Rehle T, Simbayi LC et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning tide Among Teenagers? HSRC Press, Cape Town, South Africa (2009).
  • Stone A, Harrison PF. Microbicides – Ways Forward. Alliance for Microbicide Development, Silver Spring, MD, USA (2010).
  • Stein ZA. HIV prevention: the need for methods women can use. Am. J. Public Health 80(4), 460–462 (1990).
  • Richardson BA, Lavreys L, Martin HL Jr et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex. Transm. Dis. 28(7), 394–400 (2001).
  • Kreiss J, Ngugi E, Holmes K et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268(4), 477–482 (1992).
  • Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339(8), 504–510 (1998).
  • Van Damme L, Ramjee G, Alary M et al.; COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360(9338), 971–977 (2002).
  • Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3(1), e1474 (2008).
  • Peterson L, Nanda K, Opoku BK et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2(12), e1312 (2007).
  • Abdool Karim SS, Richardson BA, Ramjee G et al.; HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7), 957–966 (2011).
  • Lagenaur LA, Sanders-Beer BE, Brichacek B et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 4(6), 648–657 (2011).
  • Pearce-Pratt R, Phillips DM. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 54(1), 173–182 (1996).
  • Saifuddin M, Doncel G, Tsai L et al. Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. Presented at: Microbicides 2008 conference. Delhi, India, 24–27 February 2008.
  • Rusconi S, Moonis M, Merrill DP et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40(1), 234–236 (1996).
  • Lewis M, Wagner W, Yalley-Ogunro J, Greenhouse J, Profy A. Efficacy of PRO 2000 gel in a macaque model for vaginal HIV transmission [Abstract A-191]. Presented at: Microbicides 2002 Conference. Antwerp, Belgium 12–15 May 2002).
  • Conrad. Investigator’s brochure: sodium cellulose sulfate 6% vaginal gel. (2006).
  • Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect. Dis. 5(6), 374–382 (2005).
  • Scordi-Bello IA, Mosoian A, He C et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49(9), 3607–3615 (2005).
  • Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654), 1977–1987 (2008).
  • Van Damme L, Govinden R, Mirembe FM et al.; CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463–472 (2008).
  • Doncel GF, Chandra N, Fichorova RN. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 37(Suppl. 3), S174–S180 (2004).
  • Abdool Karim Q, Abdool Karim SS, Frohlich JA et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168–1174 (2010).
  • Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378(9787), 279–281 (2011).
  • Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306(5695), 485–487 (2004).
  • Harman S, Herrera C, Armanesco N et al. L’644, a cholesterol derivatized version of the gp41 fusion peptide C34, provides superior activity in preclinical microbicide assays [abstract 19]. Presented at: 2010 International Microbicides Conference. PA, USA 56(5), 2347-2356 (2010).
  • Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J. Acquir. Immune Defic. Syndr. 58(2), 207–210 (2011).
  • Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 374(9687), 416–422 (2009).
  • Voeller B. AIDS and heterosexual anal intercourse. Arch. Sex. Behav. 20(3), 233–276 (1991).
  • Gross M, Holte SE, Marmor M et al. Anal sex among HIV-seronegative women at high risk of HIV exposure. JAIDS 24, 393–398 (2000).
  • Halperin DT. Heterosexual anal intercourse: prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS 13(12), 717–730 (1999).
  • Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex. Transm. Infect. 85(6), 411–415 (2009).
  • Schwandt M, Morris C, Ferguson A, Ngugi E, Moses S. Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. Sex. Transm. Infect. 82(5), 392–396 (2006).
  • van Oosterhout JJ, Bodasing N, Kumwenda JJ et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop. Med. Int. Health 10(5), 464–470 (2005).
  • Nachega JB, Stein DM, Lehman DA et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res. Hum. Retroviruses 20(10), 1053–1056 (2004).
  • Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int. J. STD AIDS 16(1), 38–41 (2005).
  • Committee on the Methodological Challenges in HIV Prevention Trials. Methodological Challenges in Biomedical HIV Prevention Trials. Lagakos SW, Gable AR (Eds). The National Academy Press, DC, USA (2008).
  • Hendrix C, Minnis A, Guddera V et al. MTN-001: A Phase 2 Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations [Abstract 35LB]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. MA, USA 27 February–2 March 2011.
  • Anton PA, Cranston RD, Kashuba A et al. RMP-02/MTN-006: A Phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of Tenofovir 1% gel compared with oral Tenofovir Disoproxil Fumarate. AIDS Res. Hum. Retroviruses (2012).
  • Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J. Predicting the Impact of ART and PrEP with Overlapping Regimens on HIV Transmission and Drug Resistance in South Africa [abstract #98LB]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. MA, USA 27 February–2 March 2011.
  • Grant RM, Lama JR, Anderson PL et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587–2599 (2010).
  • Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles’ heel of innovations in HIV prevention? BMJ 332(7541), 605–607 (2006).
  • Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 3(5), e2077 (2008).
  • Auvert B, Taljaard D, Rech D et al. Effect of the Orange Farm (South Africa) male circumcision roll-out (ANRS-12126) on the spread of HIV [abstract WELBC02]. Presented at: Sixth International AIDS Society Conference. Rome, Italy 19 July 2011.
  • Baeten JM, Donnell D, Ndase P et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367(5), 399–410 (2012).
  • Thigpen MC, Kebaabetswe PM, Paxton LA et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367(5), 423–434 (2012).
  • Cohen MS, Chen YQ, McCauley M et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6), 493–505 (2011).
  • Karim QA, Kharsany AB, Frohlich JA et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int. J. Epidemiol. 40(4), 922–930 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.